Impact of empagliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the emmy trial
Clinical Research in Cardiology · 2025-05 · 114 (5) · 629-639
DOI: 10.1007/s00392-024-02523-1 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Research in Cardiology, online erschienen am 16.09.2024. Verfasst von Nora Schwegel und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, University Heart Center Graz, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Heart Ventricles, Myocardial Infarction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Graz.
Abstract (Originalsprache)
Background
Empagliflozin administered after acute myocardial infarction proofed to improve cardiometabolic parameters and biomarkers, but the impact on cardiac function is still largely unknown. The aim of this post-hoc echocardiographic sub-analysis of the EMMY trial was to provide in-depth echocardiographic analysis on the effects of empagliflozin versus placebo on standard and novel echocardiographic structural and functional parameters after acute myocardial infarction.
Methods
In this post-hoc analysis of the EMMY trial a subset of 313 patients (157 empagliflozin vs. 156 placebo) was enrolled for post-processing analysis of echocardiographic structural and functional parameters. On top of two-dimensional and Doppler parameters, myocardial deformation analyses were performed to assess ventricular and atrial strain values.
Results
Left ventricular volumes showed significant differences in favor of empagliflozin over the course of the trial (change in left ventricular end-diastolic volume median [interquartile range] 8 [−3;19]% versus 13 [0;29]%, p = 0.048; left ventricular end-systolic volume −3 [−15;12]% versus 4 [−12;18]%, p = 0.044). This effect persisted after adjusting for baseline values, age, and sex. Left ventricular systolic and diastolic function overall improved over the course of the trial and parameters for diastolic function showed a distinct trend between groups but did not meet statistical significance in this cohort.
Conclusion
In this post-hoc analysis among patients with acute myocardial infarction, treatment with empagliflozin resulted in a significant beneficial effect on left ventricular end-diastolic and end-systolic volume, without significantly improving left ventricular or right ventricular functional parameters compared to placebo after 26 weeks. ClinicalTrials.gov registration NCT03087773. Graphical abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, University Heart Center Graz, Medical University of Graz, Graz, Austria.
- Division of Cardiology, University Heart Center Graz, Medical University of Graz, Graz, Austria. ewald.kolesnik@medunigraz.at.
- Trials Unit for Interdisciplinary Metabolic Medicine, Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
- Department of Cardiology and Intensive Care Medicine, Hospital Graz II, West Location, Graz, Austria.
- Department of Cardiology, Public Hospital Klagenfurt Am Woerthersee, Klagenfurt Am Woerthersee, Austria.
- Department of Cardiology, Medical University of Vienna, Vienna, Austria.
Förderung
- Medical University of Graz
Zitieren
APA
Schwegel, N., Strohhofer, C., Kolesnik, E., Oltean, S., Hüttmair, A., Pipp, C., Benedikt, M., Verheyen, N., Gollmer, J., Ablasser, K., Wallner, M., Santner, V., Tripolt, N., Pferschy, P., Zechner, P., Alber, H., Siller-Matula, J. M., Kopp, K., Zirlik, A., …, & von Lewinski, D. (2025). Impact of empagliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the emmy trial. Clinical Research in Cardiology, 114(5), 629-639. https://doi.org/10.1007/s00392-024-02523-1
Vancouver
Schwegel N, Strohhofer C, Kolesnik E, Oltean S, Hüttmair A, Pipp C, et al. Impact of empagliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the emmy trial. Clinical Research in Cardiology. 2025;114(5):629-639. doi:10.1007/s00392-024-02523-1
BibTeX
@article{Schwegel2025,
author = {Schwegel, Nora and Strohhofer, Christoph and Kolesnik, Ewald and Oltean, Sabrina and Hüttmair, Alexander and Pipp, Christian and Benedikt, Martin and Verheyen, Nicolas and Gollmer, Johannes and Ablasser, Klemens and Wallner, Markus and Santner, Viktoria and Tripolt, Norbert and Pferschy, Peter and Zechner, Peter and Alber, Hannes and Siller-Matula, Jolanta M and Kopp, Kristen and Zirlik, Andreas and Aziz, Faisal and Sourij, Harald and von Lewinski, Dirk},
title = {Impact of empagliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the emmy trial},
journal = {Clinical Research in Cardiology},
year = {2025},
volume = {114},
number = {5},
pages = {629--639},
doi = {10.1007/s00392-024-02523-1}
}
EUVIMED